Comparative Pharmacology
Head-to-head clinical analysis: LOPRESSOR HCT versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPRESSOR HCT versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
LOPRESSOR HCT vs PROPRANOLOL HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and reduces CNS sympathetic outflow.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
Initial: 40 mg orally twice daily; maintenance: 120-240 mg/day in 2-3 divided doses. Maximum: 640 mg/day. For hypertension, start 40 mg twice daily, increase gradually.
None Documented
None Documented
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Terminal elimination half-life is 3–6 hours, but clinical effects (e.g., beta-blockade) persist longer due to prolonged receptor occupancy. Half-life may increase in hepatic impairment.
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Primarily hepatic metabolism (>99%) with <1% excreted unchanged in urine. Metabolites are excreted renally. Fecal elimination is minimal.
Category C
Category C
Beta-Blocker/Thiazide Diuretic Combination
Beta-Blocker